查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1908235

寡核苷酸CDMO市场规模、份额和趋势分析报告：按服务、类型、应用、最终用途、地区和细分市场预测（2025-2033年）

Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Service, By Type, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

寡核苷酸CDMO市场概览

2024年全球寡核苷酸CDMO市场规模估计为9.1178亿美元，预计2033年将达到31.6897亿美元。

预计从 2025 年到 2033 年，该市场将以 14.98% 的复合年增长率成长。推动市场成长的因素包括：反义和 siRNA 疗法的临床研发管线不断增加、除疫苗外，基于 mRNA 的疗法的应用日益广泛，以及生物技术公司为降低生产复杂性而增加的外包。

此外，RNA疗法和反义疗法研发管线的不断增长，也推动了对专业生产合作伙伴的需求，以帮助扩大生产规模。随着这些候选药物进入后期临床试验阶段，申办方面临着产能限制和日益严格的纯度要求，因此他们转向经验丰富的合约研发生产机构（CDMO），以实现可扩展且符合规范的生产。在多个研发阶段对符合GMP标准的原料的需求，也推动了外包趋势，从而促进了该领域契约製造服务的稳定成长。

此外，寡核苷酸化学日益复杂，需要先进的合成平台和分析能力，而许多新兴生物技术公司无法自行开发这些平台和能力，这进一步推动了市场成长。偶联寡核苷酸、先进递送系统和更长序列等多项进展带来了额外的技术挑战，促使企业依赖拥有成熟技术的合约研发生产机构（CDMO）。因此，能够提供高产率、低杂质含量和灵活批量放大生产的技术先进的供应商在整个研发过程中变得至关重要。

目录

第一章调查方法和范围

第二章执行摘要

3. 寡核苷酸CDMO市场：变数、趋势和范围

  • 市场趋势展望
  • 寡核苷酸CDMO市场的市场动态
  • 技术展望
  • 定价模式分析
  • 关税影响分析
  • 供应链分析
  • 市场分析工具

第四章 寡核苷酸CDMO市场：依服务类型分類的估算与趋势分析

  • 全球寡核苷酸CDMO市场服务变化分析
  • 全球寡核苷酸CDMO市场规模及趋势分析（依服务类型划分，2021-2033年）
  • 契约製造
  • 合约开发

第五章 寡核苷酸CDMO市场按类型划分、估算和趋势分析

  • 全球寡核苷酸CDMO市场类型变异分析
  • 全球寡核苷酸CDMO市场规模及趋势分析（按类型划分）（2021-2033年）
  • 反义寡核苷酸
  • 小干扰RNA
  • 其他寡核苷酸

第六章：寡核苷酸CDMO市场：按应用分類的估算与趋势分析

  • 全球寡核苷酸CDMO市场使用情形变化分析
  • 全球寡核苷酸CDMO市场规模及趋势分析（依应用领域划分，2021-2033年）
  • 治疗
  • 研究
  • 诊断

7. 寡核苷酸CDMO市场：最终用途、估算与趋势分析

  • 全球寡核苷酸CDMO市场最终用途差异分析
  • 全球寡核苷酸CDMO市场规模及趋势分析（依最终用途划分），2021-2033年
  • 製药和生物製药公司
  • 诊断公司
  • 其他的

8. 寡核苷酸CDMO市场按服务、最终用途、地区分類的预测和趋势分析

  • 区域市场概览
  • 全球市场概览（按地区划分）
  • 市场规模、预测与趋势分析（2021-2033）：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 阿曼
    • 卡达

第九章 竞争情势

  • 公司分类
    • 市场领导
    • 新兴企业
  • 寡核苷酸CDMO市占率分析，2024年
  • 公司简介
    • PolyPeptide Group
    • STA Pharmaceutical Co. Ltd.
    • Bachem
    • Creative Peptides
    • Aurigene Pharmaceutical Services Ltd.
    • Merck KGaA
    • EUROAPI
    • Curia Global, Inc.
    • CordenPharm
    • Sylentis, SA
Product Code: GVR-4-68040-832-9

Oligonucleotide CDMO Market Summary

The global oligonucleotide CDMO market size was estimated at USD 911.78 million in 2024 and is projected to reach USD 3,168.97 million by 2033, growing at a CAGR of 14.98% from 2025 to 2033. The market is driven by the rising clinical pipeline of antisense and siRNA therapies, growing adoption of mRNA-based therapeutics beyond vaccines, and increasing outsourcing by biotech firms to reduce manufacturing complexity.

In addition, the increasing number of pipeline of RNA-based and antisense therapeutics is driving the need for specialized manufacturing partners to help them scale production. As these candidates progress into late-stage clinical trials, sponsors encounter capacity constraints and heightened purity requirements, prompting a shift toward experienced contract development and manufacturing organizations (CDMOs) for scalable and compliant production. The need for consistent GMP-grade materials across multiple development phases further strengthens outsourcing trends and supports the steady uptake of contract manufacturing services in this domain.

Furthermore, the growing complexity of oligonucleotide chemistry, which requires sophisticated synthesis platforms and analytical capabilities that many emerging biotech firms cannot develop internally is also contributing to market growth. Several advancements such as conjugated oligos, advanced delivery systems, and long-chain sequences is adding additional technical challenges which is encouraging companies to depend on CDMOs with proven expertise. Thus, technologically advanced providers that can deliver high yield, reduced impurity profiles, and flexible batch scaling are becoming crucial across the development range.

Global Oligonucleotide CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oligonucleotide CDMO market report based on service, type, application, end use, and region:

  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Manufacturing
  • Contract Development
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Antisense Oligonucleotides
  • Small Interfering RNA
  • Other Oligonucleotides
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Therapeutic
  • Research
  • Diagnostic
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biopharmaceutical Companies
  • Diagnostic Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Norway
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Landscape Insights

Chapter 3. Oligonucleotide CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Oligonucleotide CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunities
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Supply Chain Analysis
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Oligonucleotide CDMO Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Oligonucleotide CDMO Market Service Movement Analysis
  • 4.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
  • 4.4. Contract Manufacturing
    • 4.4.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5. Contract Development
    • 4.5.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oligonucleotide CDMO Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Oligonucleotide CDMO Market Type Movement Analysis
  • 5.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Antisense Oligonucleotides
    • 5.4.1. Antisense Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Small Interfering RNA
    • 5.5.1. Small Interfering RNA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Other Oligonucleotides
    • 5.6.1. Other Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oligonucleotide CDMO Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Oligonucleotide CDMO Market Application Movement Analysis
  • 6.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Therapeutic
    • 6.4.1. Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Research
    • 6.5.1. Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Diagnostic
    • 6.6.1. Diagnostic Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Oligonucleotide CDMO Market End Use Movement Analysis
  • 7.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Pharmaceutical and Biopharmaceutical Companies
    • 7.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Diagnostic Companies
    • 7.5.1. Diagnostic Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis by Product, Service, End Use

  • 8.1. Regional Market Dashboard
  • 8.2. Global Regional Market Snapshot
  • 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.6. Oman
      • 8.8.6.1. Key Country Dynamics
      • 8.8.6.2. Competitive Scenario
      • 8.8.6.3. Regulatory Framework
      • 8.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.7. Qatar
      • 8.8.7.1. Key Country Dynamics
      • 8.8.7.2. Competitive Scenario
      • 8.8.7.3. Regulatory Framework
      • 8.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Oligonucleotide CDMO Market Share Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. PolyPeptide Group
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product/Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. STA Pharmaceutical Co. Ltd.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product/Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Bachem
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product/Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Creative Peptides
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product/Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Aurigene Pharmaceutical Services Ltd.
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product/Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Merck KGaA
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product/Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. EUROAPI
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product/Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Curia Global, Inc.
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product/Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. CordenPharm
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product/Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Sylentis, S.A.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product/Service Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 North America Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 4 North America Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 5 North America Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 6 North America Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 8 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 9 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 11 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 12 Canada Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 13 Canada Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 14 Canada Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 15 Canada Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 17 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 21 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 23 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 24 Europe Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 25 UK Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 26 UK Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 27 UK Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 28 UK Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 29 Germany Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 30 Germany Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 31 Germany Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 32 Germany Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 33 France Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 34 France Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 35 France Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 36 France Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 37 Spain Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 38 Spain Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 39 Spain Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 40 Spain Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 41 Italy Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 42 Italy Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 44 Italy Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 45 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 46 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 47 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 48 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 49 Norway Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 50 Norway Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 51 Norway Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 52 Norway Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 53 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 54 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 55 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 56 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 62 Japan Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 63 Japan Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 64 Japan Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 65 Japan Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 66 China Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 67 China Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 68 China Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 69 China Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 70 India Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 71 India Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 72 India Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 73 India Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 74 Australia Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 75 Australia Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 76 Australia Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 77 Australia Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 78 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 79 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 80 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 81 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 82 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 83 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 84 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 85 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 86 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 87 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 88 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 89 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 90 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 91 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 92 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 93 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 94 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 95 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 96 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 97 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 98 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 99 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 100 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 101 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 102 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 103 MEA Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 104 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 105 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 106 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 107 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 111 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 112 UAE Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 113 UAE Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 114 UAE Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 115 UAE Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 116 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 117 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 118 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 119 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 120 Oman Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 121 Oman Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 122 Oman Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 123 Oman Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 124 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 125 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 126 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 127 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Oligonucleotide CDMO Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Commodity Flow Analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD Model Sizing & Forecasting
  • Fig. 10 Bottom-up Approach
  • Fig. 11 Market Snapshot
  • Fig. 12 Segment Snapshot
  • Fig. 13 Competitive Landscape Snapshot
  • Fig. 14 Parent Market Outlook, 2024 (USD Million)
  • Fig. 15 Ancillary Market Outlook, 2024 (USD Million)
  • Fig. 16 Oligonucleotide CDMO Market Dynamics
  • Fig. 17 Porter's Five Forces Analysis
  • Fig. 18 PESTEL by SWOT Analysis
  • Fig. 19 Oligonucleotide CDMO Market Service Outlook: Segment Dashboard
  • Fig. 20 Oligonucleotide CDMO Market, by Service Segment: Market Share, 2025 & 2033
  • Fig. 21 Contract Manufacturing Market Estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Oligonucleotide CDMO Market Type outlook: Segment dashboard
  • Fig. 24 Oligonucleotide CDMO Market, by Type Segment: Market Share, 2025 & 2033
  • Fig. 25 Antisense Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Small Interfering RNA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Other Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Oligonucleotide CDMO Market Application outlook: Segment dashboard
  • Fig. 29 Oligonucleotide CDMO Market, by Application Segment: Market Share, 2025 & 2033
  • Fig. 30 Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Diagnostic Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Oligonucleotide CDMO Market End Use Outlook: Segment Dashboard
  • Fig. 34 Oligonucleotide CDMO Market, by End Use Segment: Market Share, 2025 & 2033
  • Fig. 35 Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Diagnostic Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Regional marketplace: Key Takeaways
  • Fig. 39 North America Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 U.S. Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Spain Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Norway Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Sweden Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Thailand Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Brazil Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Argentina Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 MEA Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 South Africa Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Saudi Arabia Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Kuwait Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 UAE Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Oman Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Qatar Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Market Participant Categorization
  • Fig. 95 Heat Map Analysis